Phase 4
Completed N=174
Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients
Source: ClinicalTrials.gov NCT01382303 ↗Enrolled (actual)
174
Serious AEs
0.0%
Results posted
Jun 2017
Primary outcomePrimary: Percentage Change in Proteinuia — -23; -4 % change from baseline
◆ Published Evidence
Established
36citations · ~3 / year
Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study.
Summary
This multi-center, randomized controlled study aims to evaluate the effects of pentoxifylline on proteinuria in Korean type 2 diabetic patients.
Linked Publications (2)
-
Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study.
-
Antioxidants for adults with chronic kidney disease.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage Change in Proteinuia |
-23; -4 | — |
| SECONDARY Percentage Change in Albuminuria |
-10; -6 | — |
| SECONDARY Mean Change of eGFR |
-1.05; -3.59 | — |
| SECONDARY Mean Change of Creatinine |
0.03; 0.04 | — |
| SECONDARY Mean Change of Fasting Glucose |
-10.0; 8.4 | — |
| SECONDARY Mean Change of TNF-a |
-0.24; 0.14 | — |
Eligibility Criteria
Inclusion Criteria
- type 2 diabetes mellitus
- age >=20 years
- spot urine albumin/creatinine ratio > 30mg/g in two consecutive measurements
- patients on ACE-inhibitor or ARB as an anti-hypertensive drug
- blood pressure 2.0mg/dl
- severe liver disease or AST, ALT > 3* ULM
- taking systemic steroid in 1 month
- pregnant or plan to become pregnant during the clinical trial
- lactation
Data sourced from ClinicalTrials.gov (NCT01382303) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.